Most EGFRex20ins driver mutations in NSCLC are insensitive to first- and second-generation EGFR inhibitors [44–46], except osimertinib, which exhibits partial activity against some EGFRex20ins driver mutations in preclinical studies [39, 45, 47]. Here, EGFR is linked to non-small cell lung carcinoma.